Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that Imuvert consistently protected against alopecia induced by certain chemotherapy drugs in rats, potentially mediated by a monocyte-derived cytokine like interleukin-1.

This review discusses the cutaneous manifestations associated with HIV infection, highlighting that these skin conditions often present atypically and are more severe compared to those in non-HIV-infected individuals; it reports no new clinical findings.

In this study, researchers developed a rapid platform using primary human lung tissues to identify SARS-CoV-2 targets and test antiviral compounds, achieving highly reproducible results across viral variants.

This review discusses diagnostic approaches for childhood skin diseases with fever through clinical observations and covers recent advances in understanding the pathogenesis and epidemiology of related infections, without reporting new clinical results.

This compilation details various potential side effects and interactions of vitamin A, but it reports no new research findings.

This article discusses the development and clinical progress of PROTAC technology, particularly focusing on the New Drug Application for vepdegestrant, an estrogen receptor-targeting PROTAC, marking significant advancements in targeted protein degradation therapies.

In this study, peginterferon alfa-2b plus ribavirin therapy in hepatitis C patients was associated with serious adverse drug reactions in 20% of cases, highlighting differences from clinical trial findings.

This case report documents a young woman who experienced a visual field defect similar to those linked to vigabatrin use, despite treatment only with valproic acid and carbamazepine, suggestive of a possible metabolic vulnerability in certain patients with specific genetic backgrounds.

This study identified known and potential novel adverse events, such as squamous cell carcinoma and dehydration, for vismodegib, underlining the importance of monitoring especially in the first two months of treatment.

This abstract lists numerous dermatological side effects and reactions associated with various medications but reports no new research findings.

The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.

This 104-week follow-up trial found that baricitinib is effective and safe for treating severe alopecia areata but requires continuous use to sustain hair regrowth. The drug is included in the NVDV guidelines and reimbursed by Dutch insurers for this purpose.

This study reports that hedgehog pathway inhibitors, sonidegib and vismodegib, showed distinct adverse event patterns in real-world data, suggesting the need for further research to confirm these findings.

In the phase 3 CAPItello-291 trial, capivasertib combined with fulvestrant significantly increased progression-free survival in patients with advanced breast cancer with specific genetic alterations, but the authors highlight that managing side effects like diarrhea, rash, and hyperglycemia is crucial for optimizing treatment adherence and outcomes.

In this phase 3 trial, baricitinib showed effectiveness and safety in both adolescents and adults with severe alopecia areata, with adolescents achieving higher response rates despite more severe baseline conditions, suggesting the advantages of early treatment.

This article describes viDA Therapeutics Inc.'s focus on developing new drugs for age-related conditions using their proprietary granzyme-based approach but reports no clinical outcomes, primarily discussing their funding and business strategy.

Tavaborole is a safe and effective toenail fungus treatment, with the 5% solution being the best option.

Ivarmacitinib effectively regrows hair in severe alopecia areata.

Baricitinib helps regrow hair in teens with severe alopecia areata.

This study found that vinblastine treatment rapidly increased platelet counts in childhood refractory immune thrombocytopenia, providing effective control of bleeding symptoms, although side effects like neuropathic pain were common and resolved with dose adjustments.

This study found extensive real-world and clinical trial exposure to baricitinib across various disease states, ages, and racial populations, contributing data to its overall profile.

This case report suggests that hair loss may be a potential adverse effect of rivaroxaban, though it is not listed in the product characteristics.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

In this study, a UK expert panel discussed strategies for managing common side effects of vismodegib, a hedgehog pathway inhibitor used for advanced basal cell carcinoma, concluding that adverse events like taste disturbances and muscle cramps can be effectively managed to optimize treatment duration.

In this systematic review, animal studies showed that cytarabine causes multi-organ toxicities, notably neurotoxicity, linked to oxidative stress and other mechanisms, though study quality raises concerns about reliability and translation to human outcomes.

This study found that vismodegib was effective in treating basal cell carcinoma, achieving complete remission in some patients; however, significant side effects often required careful management to prevent therapy suspension, which can lead to resistance.

This study examined treatments for emesis in young Alexander disease patients, finding that 95% responded positively to valproic acid, which was more effective than anti-reflux medications or cyproheptadine, though some adverse effects require monitoring.

This study suggests that combining baricitinib with narrowband UV-B therapy is an effective and well-tolerated approach for treating active nonsegmental vitiligo.

This review discusses several new pharmacological products, including those for cardiovascular prevention and overactive bladder, but notes challenges in defining their therapeutic roles and provides safety updates on existing medications; it reports no new clinical results.

This article reviews adverse drug reactions, emphasizes methods of prevention, and encourages reporting to the FDA's medWatch program, but presents no new study findings.